We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

85 hedge funds and large institutions have $248M invested in AEON Biopharma in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

12% more capital invested

Capital invested by funds: $222M → $248M (+$26.3M)

5% more funds holding

Funds holding: 81 → 85 (+4)

0.07% more ownership

Funds ownership: 1.17% → 1.24% (+0.07%)

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

Holders
85
Holders Change
+4
Holders Change %
+4.94%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
13
Reduced
16
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CIM
Cowen Investment Management
New York
+$5.72M
2
WCMNY
Westchester Capital Management (New York)
New York
+$5.5M
3
MC
Meteora Capital
Florida
+$5.26M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.87M
5
DFCM
Dark Forest Capital Management
Puerto Rico
+$3.01M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$4.68M
2
Citadel Advisors
Citadel Advisors
Florida
-$4.12M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$3.87M
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$3.43M
5
Calamos Advisors
Calamos Advisors
Illinois
-$2.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
76
Landscape Capital Management
New Jersey
$207K +$206K +287 New
Barclays
77
Barclays
United Kingdom
$207K – – –
TAM
78
Terrapin Asset Management
Florida
$201K +$199K +278 New
AA
79
Ancora Advisors
Ohio
$169K – – –
Geode Capital Management
80
Geode Capital Management
Massachusetts
$148K – – –
FTUS
81
Flow Traders U.S.
New York
$103K -$86K -120 -46%
6CM
82
683 Capital Management
New York
$101K – – –
BlackRock
83
BlackRock
New York
$101K – – –
FC
84
Foursixthree Capital
New York
$101K +$99.6K +139 New
UBS Group
85
UBS Group
Switzerland
$8.06K -$23.6K -33 -75%
UOC
86
UBS O'Connor
Illinois
– -$4.68M -6,601 Closed
BNP Paribas Financial Markets
87
BNP Paribas Financial Markets
France
– -$3.43M -6,429 Closed
Parallax Volatility Advisers
88
Parallax Volatility Advisers
California
– -$3.87M -5,452 Closed
Calamos Advisors
89
Calamos Advisors
Illinois
– -$2.46M -3,472 Closed
Alyeska Investment Group
90
Alyeska Investment Group
Illinois
– -$2.36M -3,333 Closed
CF
91
Cantor Fitzgerald
New York
– -$1.68M -2,364 Closed
HighTower Advisors
92
HighTower Advisors
Illinois
– -$517K -728 Closed
BCM
93
Basso Capital Management
Connecticut
– -$363K -511 Closed
1 2 3
4

AEON Hedge Fund Activity: Q4 2022 in Review

85 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2022, worth a combined $248M — up 12% from $222M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AEON positions and 8 closed out — a net gain of 5 holders — while 13 added to existing stakes and 16 trimmed.

The largest buyer was Cowen Investment Management, opening a new position worth an estimated $5.72M. The largest seller was UBS O'Connor, exiting entirely with an estimated $4.68M sold.

  • 85 institutional investors held AEON Biopharma (AEON) as of Q4 2022, up from 81 in Q3 2022.
  • Funds reported $248M of AEON Biopharma stock for Q4 2022, up 12% quarter-over-quarter.
  • 13 funds opened new AEON Biopharma positions in Q4 2022 and 8 closed out, a net change of +5 holders.
  • The largest AEON Biopharma buyer in Q4 2022 was Cowen Investment Management, an estimated $5.72M added.
  • The largest AEON Biopharma seller in Q4 2022 was UBS O'Connor, an estimated $4.68M sold.

Based on aggregated 13F filings for Q4 2022.